Investment
Features
FeesSafety
Academy
More
Pluang+

eGain downgraded to Neutral with price target cut after weak 2027 outlook despite Q4 earnings beat.

Analyst Insights
08 Sep 2026
Andrew Wynn
View Source
Bearish
eGain downgraded to Neutral with price target cut after weak 2027 outlook despite Q4 earnings beat.

Roth/MKM downgraded eGain from Buy to Neutral and cut its price target from $21 to $7 due to a weak fiscal 2027 revenue outlook. Although eGain beat Q4 earnings estimates with $0.08 per share and saw a 3% full-year revenue increase, the company forecasted a revenue decline for 2027. AI customer revenue grew strongly, but declining legacy revenue weighed on the outlook. The downgrade reflects concerns over near-term growth despite positive quarterly results and industry recognition from Gartner.

More News

Intel shares jump on High-NA EUV tech progress and $120 price target upgrade

Intel shares jump on High-NA EUV tech progress and $120 price target upgrade

Intel's stock surged after Northland Securities upgraded it from "Market Perform" to "Outperform" with a $120 price target, following Intel Foundry's progress in High Numerical Aperture Extreme Ultraviolet (High-NA EUV) lithography. Intel has process...

Market News
Bullish
1 hour ago
ABM Industries beats Q3 EPS estimates with $1.04, posts record $2.3B revenue and strong cash flow.

ABM Industries beats Q3 EPS estimates with $1.04, posts record $2.3B revenue and strong cash flow.

ABM Industries reported strong Q3 2026 results, surpassing analyst EPS estimates with $1.04 per share versus the expected $1.01. The company achieved record revenue of $2.3 billion, a 4.2% increase driven by organic and acquisition growth. Adjusted n...

Company Fundamentals
Bullish
1 hour ago
GameStop Q2 earnings show revenue drop but focus on strategic fund use and financial health.

GameStop Q2 earnings show revenue drop but focus on strategic fund use and financial health.

GameStop is set to report its Q2 2026 earnings with analysts expecting an EPS of $0.27 and revenues around $756.85 million, down from $972.20 million the previous year. The company’s own sales forecast of $780-$800 million confirms a significant reve...

Company Fundamentals
Neutral
1 hour ago
Opus Genetics gets Buy rating ahead of key gene therapy data release on Sept 9, 2026.

Opus Genetics gets Buy rating ahead of key gene therapy data release on Sept 9, 2026.

Opus Genetics, a clinical-stage biotech focused on inherited retinal diseases, received a Buy rating and $8 price target from analyst Matthew Caufield in August 2026. The company plans to release topline Phase 1/2 data for its gene therapy OPGx-BEST1...

Analyst Insights
Bullish
2 hours ago
GE to acquire CPP for $11.75B, boosting aerospace casting capacity and earnings potential

GE to acquire CPP for $11.75B, boosting aerospace casting capacity and earnings potential

General Electric (GE) announced it will acquire Consolidated Precision Products (CPP) for $11.75 billion to enhance its aerospace casting production. This strategic move aims to strengthen GE's manufacturing capabilities and accelerate engine technol...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App